tiprankstipranks
Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Hong Kong Market

Pharmaron Beijing Co., Ltd. Class H (3759) Stock Forecast & Price Target

Compare
5 Followers
See the Price Targets and Ratings of:

3759 Financial Forecast

3759 Earnings Forecast

Next quarter’s earnings estimate for 3759 is HK$0.28 with a range of HK$0.21 to HK$0.35. The previous quarter’s EPS was HK$0.19. 3759 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.32% of the time in the same period. In the last calendar year 3759 has Outperformed its overall industry.
Next quarter’s earnings estimate for 3759 is HK$0.28 with a range of HK$0.21 to HK$0.35. The previous quarter’s EPS was HK$0.19. 3759 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.32% of the time in the same period. In the last calendar year 3759 has Outperformed its overall industry.

3759 Sales Forecast

Next quarter’s sales forecast for 3759 is HK$3.61B with a range of HK$3.57B to HK$3.65B. The previous quarter’s sales results were HK$3.47B. 3759 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.45% of the time in the same period. In the last calendar year 3759 has Outperformed its overall industry.
Next quarter’s sales forecast for 3759 is HK$3.61B with a range of HK$3.57B to HK$3.65B. The previous quarter’s sales results were HK$3.47B. 3759 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.45% of the time in the same period. In the last calendar year 3759 has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
HK$21HK$22
Buy
38.71%
Upside
Reiterated
10/25/24
Jefferies Sticks to Their Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
HK$21HK$22
Buy
38.71%
Upside
Reiterated
10/25/24
Jefferies Sticks to Their Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharmaron Beijing Co., Ltd. Class H

Which Analyst Should I Follow If I Want to Buy HK:3759 and Sell After:
1 Month
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
+21.40%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +21.40% per trade.
3 Months
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
+3.77%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +3.77% per trade.
1 Year
Chris LuiJefferies
Success Rate
2/4 ratings generated profit
50%
Average Return
+7.75%
reiterated a buy rating 5 months ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.75% per trade.
2 Years
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
+20.88%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +20.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3759 Analyst Recommendation Trends

Rating
Aug 23
Oct 23
Mar 24
Sep 24
Oct 24
Strong Buy
1
2
3
3
3
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
2
3
3
3
In the current month, 3759 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3759 average Analyst price target in the past 3 months is HK$21.98.
Each month's total comprises the sum of three months' worth of ratings.

3759 Stock Forecast FAQ

What is HK:3759’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharmaron Beijing Co., Ltd. Class H’s 12-month average price target is HK$21.98.
    What is HK:3759’s upside potential, based on the analysts’ average price target?
    Pharmaron Beijing Co., Ltd. Class H has 38.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pharmaron Beijing Co., Ltd. Class H a Buy, Sell or Hold?
          Pharmaron Beijing Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Pharmaron Beijing Co., Ltd. Class H’s share price target?
            The average share price target for Pharmaron Beijing Co., Ltd. Class H is HK$21.98. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$22.00 ,and the lowest forecast is HK$22.00. The average share price target represents 38.62% Increase from the current price of HK$15.86.
              What do analysts say about Pharmaron Beijing Co., Ltd. Class H?
              Pharmaron Beijing Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of Pharmaron Beijing Co., Ltd. Class H?
                To buy shares of HK:3759, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis